0.44
-0.0293(-6.23%)
Currency In USD
| Previous Close | 0.47 |
| Open | 0.47 |
| Day High | 0.47 |
| Day Low | 0.43 |
| 52-Week High | 1.35 |
| 52-Week Low | 0.24 |
| Volume | 682,014 |
| Average Volume | 7.95M |
| Market Cap | 8.09M |
| PE | -1.34 |
| EPS | -0.33 |
| Moving Average 50 Days | 0.39 |
| Moving Average 200 Days | 0.42 |
| Change | -0.03 |
If you invested $1000 in Biomerica, Inc. (BMRA) 10 years ago, it would be worth $479.57 as of February 05, 2025 at a share price of $0.441. Whereas If you bought $1000 worth of Biomerica, Inc. (BMRA) shares 5 years ago, it would be worth $142.32 as of February 05, 2025 at a share price of $0.441.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer
GlobeNewswire Inc.
Jan 16, 2025 1:19 PM GMT
- 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer - Prostate Cancer: The Second Most Common Cancer in Men Globally IRVINE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc.
Biomerica Reports Second Quarter Fiscal 2025 Financial Results
GlobeNewswire Inc.
Jan 15, 2025 1:19 PM GMT
- Total Revenue Increases 5% Year-Over-Year - Achieves Sustained Revenue Growth, Improved Gross Margins, and Significant Cost Savings IRVINE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provide
Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
GlobeNewswire Inc.
Nov 21, 2024 1:19 PM GMT
New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) The company received three notices of allowance in countries withi